RepliCel Life Sciences Inc (TSXV:RP)
RepliCel is a regenerative medicine company developing autologous cell therapies that address diseases caused by a deficit of healthy cells required for normal healing and function.
XW Labs of Wuhan received US Orphan Drug Designation status for its lead molecule, a clinical-stage treatment for narcolepsy. XW develops novel small molecule therapeutics for CNS disorders. Narcolepsy, an orphan disease that affects 1 in 2,000 people, is caused by a loss of hypocretin neuronal cells, leading to abnormal regulation of the sleep-wake cycle. XWL-008 is aimed at treating the two major symptoms of narcolepsy, excessive daytime sleepiness and cataplexy, with fewer side effects than current medications. XW is planning to start a Phase III trial of XWL-008.
Source: China Biotoday
